Forsythoside I
Based on 1 Customer Validation
Forsythoside I is an orally active caffeoyl phenylethanoid glycoside (CPG) that can be isolated from Forsythia suspense (Thunb.) Vahl. Forsythoside I has anti-inflammatory activity and can exert a protective effect in a mouse model of acute lung injury.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.94%
- CAS 番号: 1177581-50-8
- 分子式: C29H36O15
- 分子量:624.59
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
NF-κB Signaling Compound Library
HY-L014
-
Natural Product Library
HY-L021
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Glycoside Compound Library
HY-L042
-
Oxygen Sensing Compound Library
HY-L045
-
Phenols Library
HY-L057
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Protease Inhibitor Library
HY-L147
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Cytokine Inhibitors Library
HY-L161
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Pattern Recognition Receptors Library
HY-L237
-
Mongolian Medicine Compound Library
HY-L238
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
生物活性
|
IL-6 |
IL-1β |
NLRP3 |
Caspase-1 |
Forsythoside I (50-200 μg/mL; 24 hours) can inhibit the release of pro-inflammatory cytokines and the activation of the TXNIP/NLRP3 inflammasome pathway in LPS (HY-D1056)-treated RAW264.7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LPS (HY-D1056)-treated RAW264.7 cells
-
Concentration:50, 100 and 200 μg/mL
-
Incubation Time:24 h
-
Result:Inhibited the release of pro-inflammatory cytokines IL-6, TNF-α, and IL-1β.
-
Cell Line:LPS (HY-D1056)-treated RAW264.7 cells
-
Concentration:50, 100 and 200 μg/mL
-
Incubation Time:24 h
-
Result:Reduced the protein levels of TXNIP, NLRP3, ASC, and Caspase-1 in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57/BL6 mice (18-22 g) treated LPS (HY-D1056) to induce acute lung injury[1]
-
Dosage:12.5, 25 and 50 mg/kg
-
Administration:Oral gavage; 2 days before LPS instillation
-
Result:Ameliorated LPS-induced pathological changes in lung tissues, including reduced inflammatory cell infiltration, pulmonary interstitial edema, and tissue necrosis.
Decreased lung injury score; lowered cell apoptotic rate; reduced protein concentration in BALF, W/D ratio, and MPO activity; increased SOD activity.
Downregulated levels of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in lung tissues and BALF; and suppressed the expression of TXNIP, NLRP3, ASC, and Caspase-1.
化学情報
-
CAS 番号 1177581-50-8
-
性状 Solid
-
分子量 624.59
-
分子式 C29H36O15
-
Color White to off-white
-
SMILES
O[C@H]([C@@H](OC(/C=C/C1=CC=C(O)C(O)=C1)=O)[C@@H]([C@@H](CO[C@H]2[C@@H]([C@@H]([C@H]([C@H](C)O2)O)O)O)O3)O)[C@@H]3OCCC4=CC=C(O)C(O)=C4
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶剤 & 溶解度
DMSO : 100 mg/mL (160.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Liang H, et al. Potential of Forsythoside I as a therapeutic approach for acute lung injury: Involvement of TXNIP/NLRP3 inflammasome. Mol Immunol. 2021 Jun;134:192-201. [Content Brief]
[2]. Wang FN, et al. New phenylethanoid glycosides from the fruits of forsythia suspense (thunb.) vahl. Molecules. 2009 Mar 25;14(3):1324-31. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6011 mL | 8.0053 mL | 16.0105 mL | 40.0263 mL |
| 5 mM | 0.3202 mL | 1.6011 mL | 3.2021 mL | 8.0053 mL | |
| 10 mM | 0.1601 mL | 0.8005 mL | 1.6011 mL | 4.0026 mL | |
| 15 mM | 0.1067 mL | 0.5337 mL | 1.0674 mL | 2.6684 mL | |
| 20 mM | 0.0801 mL | 0.4003 mL | 0.8005 mL | 2.0013 mL | |
| 25 mM | 0.0640 mL | 0.3202 mL | 0.6404 mL | 1.6011 mL | |
| 30 mM | 0.0534 mL | 0.2668 mL | 0.5337 mL | 1.3342 mL | |
| 40 mM | 0.0400 mL | 0.2001 mL | 0.4003 mL | 1.0007 mL | |
| 50 mM | 0.0320 mL | 0.1601 mL | 0.3202 mL | 0.8005 mL | |
| 60 mM | 0.0267 mL | 0.1334 mL | 0.2668 mL | 0.6671 mL | |
| 80 mM | 0.0200 mL | 0.1001 mL | 0.2001 mL | 0.5003 mL | |
| 100 mM | 0.0160 mL | 0.0801 mL | 0.1601 mL | 0.4003 mL |
Powered by Bioz